Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Ascendis Pharma A/S ADR (NASDAQ: ASND) closed at $194.08 down -2.14% from its previous closing price of $198.32. In other words, the price has decreased by -$2.14 from its previous closing price. On the day, 0.59 million shares were traded. ASND stock price reached its highest trading level at $197.34 during the session, while it also had its lowest trading level at $191.0928.
Ratios:
For a deeper understanding of Ascendis Pharma A/S ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 1.02.
On May 05, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $250.
On April 16, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $205.RBC Capital Mkts initiated its Outperform rating on April 16, 2025, with a $205 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when JENSEN MICHAEL WOLFF bought 9,375 shares for $194.82 per share.
PEDERSEN ANNI LOTTE KIRSTINE S bought 25,000 shares of ASND for $4,789,998 on Aug 14 ’25. On Aug 13 ’25, another insider, JENSEN FLEMMING STEEN, who serves as the Officer of the company, bought 10,000 shares for $191.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASND now has a Market Capitalization of 12009146368 and an Enterprise Value of 12050887680. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.98. Its current Enterprise Value per Revenue stands at 24.556 whereas that against EBITDA is -48.475.
Stock Price History:
The Beta on a monthly basis for ASND is 0.39, which has changed by 0.40200818 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, ASND has reached a high of $199.99, while it has fallen to a 52-week low of $111.09. The 50-Day Moving Average of the stock is 9.99%, while the 200-Day Moving Average is calculated to be 27.36%.
Shares Statistics:
For the past three months, ASND has traded an average of 466.72K shares per day and 677800 over the past ten days. A total of 60.55M shares are outstanding, with a floating share count of 60.12M. Insiders hold about 0.71% of the company’s shares, while institutions hold 104.00% stake in the company. Shares short for ASND as of 1753920000 were 2755298 with a Short Ratio of 5.90, compared to 1751241600 on 2262362. Therefore, it implies a Short% of Shares Outstanding of 2755298 and a Short% of Float of 5.47.
Earnings Estimates
Currently, 12.0 analysts are dedicated to thoroughly evaluating and rating the performance of Ascendis Pharma A/S ADR (ASND) in the stock market.The consensus estimate for the next quarter is $0.04, with high estimates of $1.09 and low estimates of -$1.83.
Analysts are recommending an EPS of between -$0.71 and -$5.3 for the fiscal current year, implying an average EPS of -$2.39. EPS for the following year is $3.01, with 14.0 analysts recommending between $7.99 and -$0.46.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $207.27M this quarter.It ranges from a high estimate of $228.4M to a low estimate of $178.76M. As of the current estimate, Ascendis Pharma A/S ADR’s year-ago sales were $57.83MFor the next quarter, 12 analysts are estimating revenue of $264.55M. There is a high estimate of $298.9M for the next quarter, whereas the lowest estimate is $215.33M.
A total of 14 analysts have provided revenue estimates for ASND’s current fiscal year. The highest revenue estimate was $777M, while the lowest revenue estimate was $653.09M, resulting in an average revenue estimate of $721.88M. In the same quarter a year ago, actual revenue was $363.64MBased on 15 analysts’ estimates, the company’s revenue will be $1.29B in the next fiscal year. The high estimate is $1.6B and the low estimate is $1.04B.
